Morgan Keegan Expects EPS of $1.19 for MEDNAX 4Q Earnings
According to a research report published today by Morgan Keegan, MEDNAX, Inc. (NYSE: MD) will report its 4Q results before the market open next Thursday, February 2.
In the report, Morgan Keegan said, “Our EPS estimate of $1.19 versus $1.12 in the prior year period is in line with the FactSet consensus. Management's guidance is $1.15-$1.20. Going forward, we expect MEDNAX to make accretive acquisitions in both neonatology and anesthesiology to augment internal growth. We will also look for continued stability in birth rates and payor mix.”
Morgan Keegan maintains its Outperform rating and $83.00 PT on MEDNAX, Inc., which closed yesterday at $71.44.
© 2014 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.